Shows a potential increased lymphoma risk with dupilumab in asthma, indicating the need for careful monitoring.
Extract The article by Ma et al. [1] suggested that lower all-cause mortality along with a putative increased lymphoma risk was associated with dupilumab use in asthma. There are several methodological issues with the data which may have affected its interpretation.
No takes yet. Share an insight, caveat, or question.
Lipworth et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: